Thrombotic microangiopathies: An illustrated review [PDF]
Research and Practice in Thrombosis and Haemostasis, 2022 The thrombotic microangiopathies (TMAs) are a heterogenous group of disorders with distinct pathophysiologies that cause occlusive microvascular or macrovascular thrombosis, and are characterized by microangiopathic hemolytic anemia, thrombocytopenia ...
Mouhamed Yazan Abou-Ismail +2 more
exaly +3 more sources
A rare case report of gemcitabine-induced thrombotic microangiopathies [PDF]
SAGE Open Medical Case Reports, 2021 A 65-year-old female patient with breast cancer and soft tissue sarcoma who experienced a gemcitabine-induced thrombotic microangiopathies manifestation visited the emergency department.
Mohammed Ali Madkhali
exaly +3 more sources
Complement Mediated Endothelial Damage in Thrombotic Microangiopathies [PDF]
Frontiers in Medicine, 2022 Thrombotic microangiopathies (TMA) constitute a group of different disorders that have a common underlying mechanism: the endothelial damage. These disorders may exhibit different mechanisms of endothelial injury depending on the pathological trigger ...
Miquel Blasco +7 more
doaj +2 more sources
Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review [PDF]
BMC NephrologyComplement-mediated thrombotic microangiopathies (CM-TMA) are rare and life-threatening disorders characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
Pilar Musalem
doaj +2 more sources
HELLP Syndrome and Differential Diagnosis with Other Thrombotic Microangiopathies in Pregnancy [PDF]
DiagnosticsThrombotic microangiopathies (TMAs) comprise a distinct group of diseases with different manifestations that can occur in both pediatric and adult patients.
Stefano Raffaele Giannubilo +3 more
doaj +2 more sources
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre [PDF]
BMC Nephrology, 2021 Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the
Maximilien Grall +14 more
doaj +2 more sources
Thrombotic microangiopathies: An update
Hematology, 2006 Thrombotic microangiopathies (TMA) are microvascular occlusive disorders characterized by hemolytic anemia caused by fragmentation of erythrocytes and thrombocytopenia due to increased platelet aggregation and thrombus formation, eventually leading to disturbed microcirculation with reduced organ perfusion.
Massimo Franchini
exaly +3 more sources
Pregnancy as a susceptible state for thrombotic microangiopathies [PDF]
Frontiers in MedicinePregnancy and the postpartum period represent phases of heightened vulnerability to thrombotic microangiopathies (TMAs), as evidenced by distinct patterns of pregnancy-specific TMAs (e.g., preeclampsia, HELLP syndrome), as well as a higher incidence of ...
Marie Frimat +5 more
doaj +2 more sources
The utility of platelet activation biomarkers in thrombotic microangiopathies
Platelets, 2022 Primary thrombotic microangiopathies (TMAs) are observed in thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), while secondary TMAs have a wide range of etiologies. Early diagnosis and treatment of TMA are critical for patient
Mohammad Al-Tamimi +2 more
exaly +2 more sources
Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies [PDF]
Turkish Journal of Hematology, 2019 Thrombotic microangiopathies (TMAs) are multiple disease entities with different etiopathogeneses, characterized by thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytosis, variable symptoms including fever, and multi-organ failure
Gina Zini, Raimondo De Cristofar
doaj +2 more sources